Caris Life Sciences and Genentech Partner on Cancer Target Discovery
Caris Life Sciences has entered a multi-year collaboration and license agreement with Genentech to identify and validate new oncology targets in solid tumors. The agreement includes $25 million in upfront and near-term payments and up to $1.1 billion in potential milestone payments.